<DOC>
	<DOCNO>NCT01397760</DOCNO>
	<brief_summary>The purpose study describe experience use omalizumabe , real life scenario , uncontrolled severe asthmatic patient attend specialist outpatient clinic , efficacy safety . The efficacy omalizumab population observe evaluated reduction uncontrolled asthma related event , i.e . exacerbation , emergency dept . visit , hospitalization asthma-related treatment ( decrease asthma medication ) .</brief_summary>
	<brief_title>Retrospective Study Description The Use Of Omalizumab In Patients With Difficult To Control Asthma</brief_title>
	<detailed_description>Omalizumab indicate child 6 year age , diagnosis difficult control asthma , present component atopy demonstrate preferably positive skin test ( prick test ) vitro reactivity ( rast ) allergens common inhalant . Patients must also present total serum IgE level 30 700UI/mL . Children 12 year IgE level 30 300 IU/ml .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients optimal asthma treatment , good compliance response treatment accord asthma consensus ( GINA/NAEEP Latinamerican Consensus Difficult treat Asthma )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>DIFFICULT TO CONTROL ASTHMA</keyword>
	<keyword>OMALIZUMABE</keyword>
</DOC>